FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul Verweij

Research Profile

Chemicals & Drugs

Disorders

Procedures

Microbial Sensitivity Tests

Living Beings

Physiology

Fungal Drug Resistance

Concepts & Ideas

Sensitivity and Specificity

Co-author Network

Publications

TOP 3
Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.
Seyedmojtaba Seyedmousavi; Willem J G Melchers; Joseph Meletiadis; Johan W Mouton; Antonius J M M Rijs; Paul E Verweij
In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Seyedmojtaba Seyedmousavi; Paul E Verweij; Roger J M Brüggemann; Willem J G Melchers; Antonius J M M Rijs; Johan W Mouton
Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul Verweij (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Seyedmojtaba Seyedmousavi; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis.
Antimicrobial agents and chemotherapy 2013;57(4):1866-71.
2013: Seyedmojtaba Seyedmousavi; Willem J G Melchers; Joseph Meletiadis; Johan W Mouton; Antonius J M M Rijs; Paul E Verweij
In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus.
Antimicrobial agents and chemotherapy 2013;57(2):796-803.
2013: Seyedmojtaba Seyedmousavi; Paul E Verweij; Roger J M Brüggemann; Willem J G Melchers; Antonius J M M Rijs; Johan W Mouton
Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
The Journal of antimicrobial chemotherapy 2013;68(2):385-93.
2013: Paul E Verweij; Bas Zwaan; Gert H J Kema; Willem J G Melchers
Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus.
Pest management science 2013;69(2):165-70.
2013: Stefanie Henriet; Steven M Holland; Paul E Verweij; Adilia Warris
Invasive fungal infections in patients with chronic granulomatous disease.
Advances in experimental medicine and biology 2013;764():27-55.
2013: Seyedmojtaba Seyedmousavi; Paul E Verweij; Roger J M Brüggemann; Willem J G Melchers; Johan W Mouton
Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Antimicrobial agents and chemotherapy 2013;57(1):303-8.
2012: Simone M T Camps; Paul S Dyer; Corné H W Klaassen; Jacques F Meis; Willem J G Melchers; Céline M O'Gorman; Antonius J M M Rijs; Paul E Verweij
Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism.
Journal of clinical microbiology 2012;50(8):2674-80.
2012: Annelies M Zwitserloot; Joep M Galama; Peter M Hoogerbrugge; Annelies M C Mavinkurve-Groothuis; Paul E Verweij; Adilia Warris
Importance of neutropenia for development of invasive infections at various phases of treatment for hemato-oncological diseases in children.
Scandinavian journal of infectious diseases 2012;44(5):355-62.
2012: Albertine E Donker; Peter M Hoogerbrugge; Annelies M C Mavinkurve-Groothuis; Lya E van Die; Paul E Verweij; Adilia Warris
Favorable outcome of chronic disseminated candidiasis in four pediatric patients with hematological malignancies.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2012;50(3):315-9.
2012: Simone M T Camps; Bas E Dutilh; Martijn A Huynen; Antonius J M M Rijs; Eveline Snelders; Paul E Verweij; Maiken Cavling Arendrup; Willem J G Melchers
Discovery of a HapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing.
PloS one 2012;7(11):e50034.
2012: Paul E Verweij; Nienke van de Sande-Bruisma; Gert H J Kema; Willem J G Melchers
[Azole resistance in Aspergillus fumigatus in the Netherlands--increase due to environmental fungicides?].
Nederlands tijdschrift voor geneeskunde 2012;156(25):A4458.
2012: Eveline Snelders; Henrich A van der Lee; Simone M T Camps; Anna Karawajczyk; Gert H J Kema; Corné H Klaassen; Willem J G Melchers; Gijs Schaftenaar; Paul E Verweij
Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus.
PloS one 2012;7(3):e31801.
2011: Eveline Snelders; Hanka Venselaar; Rob J A Verhoeven; Paul E Verweij; Anna Karawajczyk; Gijs Schaftenaar; Willem J G Melchers
The structure-function relationship of the Aspergillus fumigatuscyp51A L98H conversion by site-directed mutagenesis: the mechanism of L98H azole resistance.
Fungal genetics and biology : FG & B 2011;48(11):1062-70.
2011: FM Verduyn Lunel; J Peter Donnelly; N M A Blijlevens; Henrich A L van der Lee; Paul E Verweij
Performance of the new Platelia Candida Plus assays for the diagnosis of invasive Candida infection in patients undergoing myeloablative therapy.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2011;49(8):848-55.
2011: Jan W M van der Linden; Frank H Van Tiel; Yvette J Debets-Ossenkopp; Greetje A Kampinga; Ed J Kuijper; Eva Mattsson; Willem J G Melchers; Bart J A Rijnders; Eveline Snelders; Paul E Verweij
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009.
Emerging infectious diseases 2011;17(10):1846-54.
2011: Seyedmojtaba Seyedmousavi; Paul E Verweij; Willem J G Melchers; Johan W Mouton
Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR.
Current opinion in pharmacology 2011;11(5):486-93.
2011: Bart Jan Kullberg; O Lortholary; P Martino; J F Meis; P Muñoz; F C Odds; J H Rex; T R Rogers; E Roilides; M Ruhnke; A J Ullmann; Ö Uzun; K Vandewoude; Paul E Verweij; J-L Vincent; M Akova; M C Arendrup; J Bille; T Calandra; M Cuenca-Estrella; Ben E de Pauw; Raoul Herbrecht; F Jacobs; M Kalin; C C Kibbler; J Peter Donnelly
European expert opinion on the management of invasive candidiasis in adults.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2011;17 Suppl 5():1-12.
2011: I M E Desar; W B C Stevens; Paul E Verweij; W J F M van der Velden
A Sézary cryptogram. Disseminated cryptococcal infection.
The Netherlands journal of medicine 2011;69(7):346, 349.
2011: Saskia Kuipers; Willem J G Melchers; Johan W Mouton; Roger J M Brüggemann; Ruud G L de Sévaux; John P F A Heesakkers; Paul E Verweij
Failure of posaconazole therapy in a renal transplant patient with invasive aspergillosis due to Aspergillus fumigatus with attenuated susceptibility to posaconazole.
Antimicrobial agents and chemotherapy 2011;55(7):3564-6.
2011: Roger J M Brüggemann; Jan W M van der Linden; Paul E Verweij; David M Burger; Adilia Warris
Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
The Pediatric infectious disease journal 2011;30(6):533-4.
2011: Paul E Verweij; S M T Camps; Gert H J Kema; W J G Melchers
Comment on: Low prevalence of resistance to azoles in Aspergillus fumigatus in a French cohort of patients treated for haematological malignancies.
The Journal of antimicrobial chemotherapy 2011;66(4):954-5; author reply 955.
2011: M A S H Mennink-Kersten; Dorien Ruegebrink; Paul E Verweij; W J Steinbach
Calcineurin-dependent galactomannan release in Aspergillus fumigatus.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2011;30(4):551-3.
2011: Jan W M Van Der Linden; Adilia Warris; Paul E Verweij
Aspergillus species intrinsically resistant to antifungal agents.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2011;49 Suppl 1():S82-9.
2011: Eveline Snelders; Willem J G Melchers; Paul E Verweij
Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?
Future microbiology 2011;6(3):335-47.
2011: Stefanie S V Henriet; Peter W M Hermans; Paul E Verweij; Elles Simonetti; Steven M Holland; Janyce A Sugui; Kyung J Kwon-Chung; Adilia Warris
Human leukocytes kill Aspergillus nidulans by reactive oxygen species-independent mechanisms.
Infection and immunity 2011;79(2):767-73.
2011: Louis Y A Chai; Alieke G Vonk; Bart Jan Kullberg; Paul E Verweij; Ineke Verschueren; Jos W M van der Meer; Leo A B Joosten; Jean-Paul Latgé; Mihai G Netea
Aspergillus fumigatus cell wall components differentially modulate host TLR2 and TLR4 responses.
Microbes and infection / Institut Pasteur 2011;13(2):151-9.
2010: Eleftheria Mavridou; Roger J M Bruggemann; Willem J G Melchers; Paul E Verweij; Johan W Mouton
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Antimicrobial agents and chemotherapy 2010;54(11):4758-64.
2010: Mihai G Netea; F van der Leij; J P H Drenth; L A B Joosten; R te Morsche; Paul E Verweij; D de Jong; Bart Jan Kullberg; J W M van der Meer
Chronic yersiniosis due to defects in the TLR5 and NOD2 recognition pathways.
The Netherlands journal of medicine 2010;68(10):310-5.
2010: Theo S Plantinga; Omar J M Hamza; Janet A Willment; Bart Ferwerda; Nicole M D van de Geer; Paul E Verweij; M I N Matee; Kathy Banahan; Luke A J O'Neill; Bart Jan Kullberg; Gordon D Brown; Andre J A M van der Ven; Mihai G Netea
Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis.
Journal of acquired immune deficiency syndromes (1999) 2010;55(1):87-94.
2010: Adilia Warris; A Onken; Peter Gaustad; W Janssen; H van der Lee; Paul E Verweij; Tore G Abrahamsen
Point-of-use filtration method for the prevention of fungal contamination of hospital water.
The Journal of hospital infection 2010;76(1):56-9.
2010: Jos Houbraken; Paul E Verweij; Anthonius J M M Rijs; Andrew M Borman; Robert A Samson
Identification of Paecilomyces variotii in clinical samples and settings.
Journal of clinical microbiology 2010;48(8):2754-61.
2010: Eveline Snelders; Anna Karawajczyk; Gijs Schaftenaar; Paul E Verweij; Willem J G Melchers
Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling.
Antimicrobial agents and chemotherapy 2010;54(6):2425-30.
2010: Jan W M van der Linden; Eveline Snelders; Jan P Arends; Simon M Daenen; Willem J G Melchers; Paul E Verweij
Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens.
Journal of clinical microbiology 2010;48(4):1478-80.
2010: Eleftheria Mavridou; Roger J M Brüggemann; Willem J G Melchers; Johan W Mouton; Paul E Verweij
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene.
Antimicrobial agents and chemotherapy 2010;54(2):860-5.
2010: G J van de Glind; C E M Gidding; C M W Verlaat; K Duthoi; A P C Backx; Paul E Verweij; Adilia Warris
Acute Cardiac Failure due to Intra-Atrial Mass Caused by Zygomycetes in an Immunocompromised Paediatric Patient.
Case reports in medicine 2010;2010():241791.
2009: Otmar R Buyne; Harry van Goor; Paul E Verweij; Robert P Bleichrodt; Thijs Hendriks
Timing and dose of tissue plasminogen activator to prevent abscess formation after surgical treatment of secondary peritonitis in the rat.
Surgical innovation 2009;16(4):299-305.
2009: Paul E Verweij; Eveline Snelders; Gert H J Kema; Emilia Mellado; Willem J G Melchers
Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?
The Lancet infectious diseases 2009;9(12):789-95.
2009: Paul E Verweij; Susan J Howard; Willem J G Melchers; David W Denning
Azole-resistance in Aspergillus: proposed nomenclature and breakpoints.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2009;12(6):141-7.
2009: Johan W Mouton; D T A Te Dorsthorst; J F G M Meis; Paul E Verweij
Dose-response relationships of three amphotericin B formulations in a non-neutropenic murine model of invasive aspergillosis.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2009;47(8):802-7.
2009: Otmar R Buyne; Robert P Bleichrodt; Ben M de Man; R M L M Lomme; Paul E Verweij; Harry van Goor; Thijs Hendriks
Tissue-type plasminogen activator prevents abscess formation but does not affect healing of bowel anastomoses and laparotomy wounds in rats with secondary peritonitis.
Surgery 2009;146(5):939-46.
2009: Frans M Verduyn Lunel; Monique Mennink; Dorien Ruegebrink; Henrich A L van der Lee; J Peter Donnelly; Nicole M A Blijlevens; Paul E Verweij
Value of Candida serum markers in patients with invasive candidiasis after myeloablative chemotherapy.
Diagnostic microbiology and infectious disease 2009;64(4):408-15.
2009: Paul E Verweij; G M González; N P Wiedrhold; C Lass-Flörl; P Warn; M Heep; M A Ghannoum; J Guinea
In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries.
Journal of chemotherapy (Florence, Italy) 2009;21(3):272-81.
2009: Eveline Snelders; Robert A G Huis In 't Veld; Antonius J M M Rijs; Gert H J Kema; Willem J G Melchers; Paul E Verweij
Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles.
Applied and environmental microbiology 2009;75(12):4053-7.
2009: Roger J M Brüggemann; Jan-Willem C Alffenaar; N M A Blijlevens; Eliane M Billaud; Jos G W Kosterink; Paul E Verweij; David Burger
Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(10):1441-58.
2009: Paul E Verweij; Johan Maertens
The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Moulds: diagnosis and treatment.
The Journal of antimicrobial chemotherapy 2009;63 Suppl 1():i31-5.
2009: Jan W M van der Linden; Rogier R Jansen; Dorine Bresters; Caroline E Visser; Suzanne E Geerlings; Ed J Kuijper; Willem J G Melchers; Paul E Verweij
Azole-resistant central nervous system aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;48(8):1111-3.
2009: FM Verduyn Lunel; J Peter Donnelly; H A L van der Lee; N M A Blijlevens; Paul E Verweij
Circulating Candida-specific anti-mannan antibodies precede invasive candidiasis in patients undergoing myelo-ablative chemotherapy.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2009;15(4):380-6.
2009: Jan W van der Linden; Adilia Warris; Jos W van der Meer; Dorine Bresters; Willem J G Melchers; Paul E Verweij
[Azole-resistant invasive aspergillosis].
Nederlands tijdschrift voor geneeskunde 2009;153():A765.
2008: Paul E Verweij; D T A Te Dorsthorst; Willem H P Janssen; Jacques Meis; Johan W Mouton
In vitro activities at pH 5.0 and pH 7.0 and in vivo efficacy of flucytosine against Aspergillus fumigatus.
Antimicrobial agents and chemotherapy 2008;52(12):4483-5.
2008: Omar J M Hamza; M I N Matee; Roger J M Brüggemann; Mainen J Moshi; Elison N M Simon; Ferdinand Mugusi; Frans H M Mikx; Henrich A L van der Lee; Paul E Verweij; Andre J A M van der Ven
Single-dose fluconazole versus standard 2-week therapy for oropharyngeal candidiasis in HIV-infected patients: a randomized, double-blind, double-dummy trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;47(10):1270-6.
2008: Otmar R Buyne; Robert P Bleichrodt; Harry van Goor; Paul E Verweij; Thijs Hendriks
Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis.
The British journal of surgery 2008;95(10):1287-93.
2008: Annelies M Zwitserloot; Adilia Warris; Louis G van't Hek; Lya E van Die; Paul E Verweij; Annelies M C Mavinkurve-Groothuis
Disseminated aspergillosis in an adolescent with acute lymphoblastic leukemia.
Pediatric blood & cancer 2008;51(3):423-6.
2008: Otmar R Buyne; Harry van Goor; Robert P Bleichrodt; Paul E Verweij; Thijs Hendriks
Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat.
Surgery 2008;144(1):66-73.
2008: Monique Mennink; Dorien Ruegebrink; Paul E Verweij
Pseudomonas aeruginosa as a cause of 1,3-beta-D-glucan assay reactivity.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(12):1930-1.
2008: Carolien J P van den Bout-van den Beukel; Omar J M Hamza; Mainen J Moshi; Mecky I N Matee; Frans Mikx; David Burger; Peter P Koopmans; Paul E Verweij; Willem G E J Schoonen; Andre J A M van der Ven
Evaluation of cytotoxic, genotoxic and CYP450 enzymatic competition effects of Tanzanian plant extracts traditionally used for treatment of fungal infections.
Basic & clinical pharmacology & toxicology 2008;102(6):515-26.
2008: Paul E Verweij; János Varga; Jos Houbraken; Antonius J M M Rijs; Frans M Verduynlunel; N M A Blijlevens; Yvonne R Shea; Steven M Holland; Adilia Warris; Willem J G Melchers; Robert A Samson
Emericella quadrilineata as cause of invasive aspergillosis.
Emerging infectious diseases 2008;14(4):566-72.
2008: Monique Mennink; Dorien Ruegebrink; Rocus R Klont; Adilia Warris; N M A Blijlevens; J Peter Donnelly; Paul E Verweij
Improved detection of circulating Aspergillus antigen by use of a modified pretreatment procedure.
Journal of clinical microbiology 2008;46(4):1391-7.
2008: János Varga; Jos Houbraken; Henrich A L Van Der Lee; Paul E Verweij; Robert A Samson
Aspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustus.
Eukaryotic cell 2008;7(4):630-8.
2008: Anna Simon; Bart Jan Kullberg; Brian Tripet; Otto Boerman; Patrick L J M Zeeuwen; Johanna van der Ven-Jongekrijg; Paul E Verweij; Joost Schalkwijk; Robert Hodges; Jos W M van der Meer; Mihai G Netea
Drosomycin-like defensin, a human homologue of Drosophila melanogaster drosomycin with antifungal activity.
Antimicrobial agents and chemotherapy 2008;52(4):1407-12.
2008: Susanne Groeneveld; Paul E Verweij; Louis Van't Hek; Jos P M Bökkerink; Adilia Warris
Amphotericin B-deoxycholate overdose due to administration error in pediatric patients.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2008;46(2):185-7.
2008: Omar J M Hamza; M I N Matee; Mainen J Moshi; E N M Simon; Ferdinand Mugusi; Frans H M Mikx; Wim H van Palenstein Helderman; Antonius J M M Rijs; Andre J A M van der Ven; Paul E Verweij
Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis.
BMC microbiology 2008;8():135.
2007: Paul E Verweij; W J F M van der Velden; J Peter Donnelly; N M A Blijlevens; Adilia Warris
[Invasive zygomycosis in patients treated for haematological malignancies].
Nederlands tijdschrift voor geneeskunde 2007;151(47):2597-602.
2007: Roxana G Vitale; Javier Afeltra; Jacques Meis; Paul E Verweij
Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium and zygomycetes.
Mycoses 2007;50(4):270-6.
2007: Otmar R Buyne; Robert P Bleichrodt; Harry van Goor; Paul E Verweij; Thijs Hendriks
Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model.
International journal of colorectal disease 2007;22(7):819-25.
2007: D T A Te Dorsthorst; R B M Groot Zwaaftink; Antonius J M M Rijs; Joseph Meletiadis; Paul E Verweij
A colorimetric and spectrophotometric method for in vitro susceptibility testing of Aspergillus species against caspofungin.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2007;45(4):351-5.
2007: Johan Maertens; Rocus R Klont; Christine Masson; Koen Theunissen; Wouter Meersseman; Katrien Lagrou; Christine Heinen; Brigitte Crépin; Johan Van Eldere; MARC TABOURET; J Peter Donnelly; Paul E Verweij
Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(10):1329-36.
2006: Joseph Meletiadis; D T A Te Dorsthorst; Paul E Verweij
The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.
International journal of antimicrobial agents 2006;28(5):439-49.
2006: Otmar R Buyne; Robert P Bleichrodt; Paul E Verweij; Hans M M Groenewoud; Harry van Goor; Thijs Hendriks
A peritonitis model with low mortality and persisting intra-abdominal abscesses.
International journal of experimental pathology 2006;87(5):361-8.
2006: Monique Mennink; Paul E Verweij
Non-culture-based diagnostics for opportunistic fungi.
Infectious disease clinics of North America 2006;20(3):711-27, viii.
2006: W J F M van der Velden; N M A Blijlevens; Rocus R Klont; J Peter Donnelly; Paul E Verweij
Primary hepatic invasive aspergillosis with progression after rituximab therapy for a post transplantation lymphoproliferative disorder.
Annals of hematology 2006;85(9):621-3.
2006: Rocus R Klont; Monique Mennink; Dorien Ruegebrink; Antonius J M M Rijs; N M A Blijlevens; J Peter Donnelly; Paul E Verweij
Paradoxical increase in circulating Aspergillus antigen during treatment with caspofungin in a patient with pulmonary aspergillosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2006;43(3):e23-5.
2006: FM Verduyn Lunel; J G M Koeleman; L Spanjaard; Christina M.J.E, Vandenbroucke-Grauls; C Schultz; Henri A Verbrugh; G Vos; A Troelstra; Ellen M Mascini; Paul E Verweij; Andreas Voss
Trends in fungaemia and antifungal susceptibility in the Netherlands.
The Netherlands journal of medicine 2006;64(7):236-42.
2006: Monique Mennink; Adilia Warris; Paul E Verweij
1,3-beta-D-glucan in patients receiving intravenous amoxicillin-clavulanic acid.
The New England journal of medicine 2006;354(26):2834-5.
2006: Eric Nulens; Emmanuel De Laere; Heidi Vandevelde; Luuk B Hilbrands; Antonius J M M Rijs; Willem J G Melchers; Paul E Verweij
Alternaria infectoria phaeohyphomycosis in a renal transplant patient.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2006;44(4):379-82.
2006: Rocus R Klont; Antonius J M M Rijs; Adilia Warris; P D J Sturm; Willem J G Melchers; Paul E Verweij
Legionella pneumophila in commercial bottled mineral water.
FEMS immunology and medical microbiology 2006;47(1):42-4.
2006: Monique Mennink; Dorien Ruegebrink; Nazhat Wasei; Willem J G Melchers; Paul E Verweij
In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis.
Journal of clinical microbiology 2006;44(5):1711-8.
2006: B A J Veldman; Paul E Verweij; N M A Blijlevens
Successful treatment of liposomal amphotericin B refractory Candida glabrata fungaemia in a patient undergoing a stem cell transplantation.
The Netherlands journal of medicine 2006;64(4):127-9.
2006: Chantal A A Van Der Graaf; Mihai G Netea; Servaas A Morré; Martin den Heijer; Paul E Verweij; Jos W M van der Meer; Bart Jan Kullberg
Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection.
European cytokine network 2006;17(1):29-34.
2006: Edith L G M Tonnaer; Theo Hafmans; Toin H van Kuppevelt; Elisabeth A M Sanders; Paul E Verweij; Jo H A J Curfs
Involvement of glycosaminoglycans in the attachment of pneumococci to nasopharyngeal epithelial cells.
Microbes and infection / Institut Pasteur 2006;8(2):316-22.
2006: Mainen J Moshi; Carolien J P van den Beukel; Omar J M Hamza; Zakaria H Mbwambo; Ramadhani O S Nondo; Pax J Masimba; M I N Matee; Modest C Kapingu; Frans Mikx; Paul E Verweij; André J A M van der Ven
Brine shrimp toxicity evaluation of some Tanzanian plants used traditionally for the treatment of fungal infections.
African journal of traditional, complementary, and alternative medicines : AJTCAM / African Networks on Ethnomedicines 2006;4(2):219-25.
2005: D T A Te Dorsthorst; Paul E Verweij; Jacques Meis; Johan W Mouton
Efficacy and pharmacodynamics of flucytosine monotherapy in a nonneutropenic murine model of invasive aspergillosis.
Antimicrobial agents and chemotherapy 2005;49(10):4220-6.
2005: Alieke G Vonk; Catharina W Wieland; Marieke Versteegen; Ineke Verschueren; Mihai G Netea; Leo A B Joostent; Paul E Verweij; Bart Jan Kullberg
Influence of endogenous pro-inflammatory cytokines on neutrophil-mediated damage of Candida albicans pseudohyphae, quantified in a modified tetrazolium dye assay.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2005;43(6):551-7.
2005: Monique Mennink; Dorien Ruegebrink; Rocus R Klont; Adilia Warris; Françoise Gavini; Huub J M Op den Camp; Paul E Verweij
Bifidobacterial lipoglycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity.
Journal of clinical microbiology 2005;43(8):3925-31.
2005: D T A Te Dorsthorst; Paul E Verweij; Jacques Meis; Johan W Mouton
Relationship between in vitro activities of amphotericin B and flucytosine and pH for clinical yeast and mold isolates.
Antimicrobial agents and chemotherapy 2005;49(8):3341-6.
2005: Rocus R Klont; Cathrien Eggink; Antonius J M M Rijs; Pieter Wesseling; Paul E Verweij
Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005;40(12):e110-2.
2005: Paul E Verweij
Advances in diagnostic testing.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2005;43 Suppl 1():S121-4.
2005: Adilia Warris; Paul E Verweij
Clinical implications of environmental sources for Aspergillus.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2005;43 Suppl 1():S59-65.
2005: Paul E Verweij; J Peter Donnelly; CE van Die; N M A Blijlevens; Bart Jan Kullberg; Ben E de Pauw
[Improved diagnostics in invasive aspergillosis and systematic monitoring in patients at high risk of infection].
Nederlands tijdschrift voor geneeskunde 2005;149(11):561-7.
2005: Joseph Meletiadis; Paul E Verweij; Debbie T A TeDorsthorst; Jacques Meis; Johan W Mouton
Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2005;43(2):133-52.
2004: Rocus R Klont; Monique Mennink; Paul E Verweij
Utility of Aspergillus antigen detection in specimens other than serum specimens.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;39(10):1467-74.
2004: Paul E Verweij; Rocus R Klont; J Peter Donnelly
Validating PCR for detecting invasive aspergillosis.
British journal of haematology 2004;127(2):235-6.
2004: D T A Te Dorsthorst; Johan W Mouton; C J P van den Beukel; H A L van der Lee; Jacques Meis; Paul E Verweij
Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
Antimicrobial agents and chemotherapy 2004;48(8):3147-50.
2004: Monique Mennink; J Peter Donnelly; Paul E Verweij
Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis.
The Lancet infectious diseases 2004;4(6):349-57.
2004: D T A Te Dorsthorst; Paul E Verweij; Jacques Meis; Nieko Punt; Johan W Mouton
In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.
Antimicrobial agents and chemotherapy 2004;48(6):2007-13.
2004: Javier Afeltra; Roxana G Vitale; Johan W Mouton; Paul E Verweij
Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.
Antimicrobial agents and chemotherapy 2004;48(4):1335-43.
2004: Frans M Verduyn Lunel; Andreas Voss; Ed J Kuijper; L B S Gelinck; Peter M Hoogerbrugge; K L Liem; Bart Jan Kullberg; Paul E Verweij
Detection of the Candida antigen mannan in cerebrospinal fluid specimens from patients suspected of having Candida meningitis.
Journal of clinical microbiology 2004;42(2):867-70.
2004: Monique Mennink; Rocus R Klont; Adilia Warris; Huub J M Op den Camp; Paul E Verweij
Bifidobacterium lipoteichoic acid and false ELISA reactivity in aspergillus antigen detection.
Lancet 2004;363(9405):325-7.
2003: Alieke G Vonk; Mihai G Netea; J H J M van Krieken; Paul E Verweij; Jos W M van der Meer; Bart Jan Kullberg
Treatment of intra-abdominal abscesses caused by Candida albicans with antifungal agents and recombinant murine granulocyte colony-stimulating factor.
Antimicrobial agents and chemotherapy 2003;47(12):3688-93.
2003: Eric Dannaoui; Jacques Meis; David Loebenberg; Paul E Verweij
Activity of posaconazole in treatment of experimental disseminated zygomycosis.
Antimicrobial agents and chemotherapy 2003;47(11):3647-50.
2003: Joseph Meletiadis; D T A Te Dorsthorst; Paul E Verweij
Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi.
Journal of clinical microbiology 2003;41(10):4718-25.
2003: Adilia Warris; Corné Klaassen; Jacques Meis; Maaike T De Ruiter; Hanneke A De Valk; Tore G Abrahamsen; Peter Gaustad; Paul E Verweij
Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains.
Journal of clinical microbiology 2003;41(9):4101-6.
2003: Roxana G Vitale; G Sybren De Hoog; Paul E Verweij
In vitro activity of amphotericin B, itraconazole, terbinafine and 5-fluocytosine against Exophiala spinifera and evaluation of post-antifungal effects.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2003;41(4):301-7.
2003: Mihai G Netea; Adilia Warris; Jos W M van der Meer; Matthew J Fenton; Trees J G Verver-Janssen; Liesbeth E H Jacobs; Tonje Andresen; Paul E Verweij; Bart Jan Kullberg
Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction.
The Journal of infectious diseases 2003;188(2):320-6.
2003: F Bosma; Andreas Voss; Henk W van Hamersvelt; Ruud G L de Sévaux; Jan Biert; Bart Jan Kullberg; W G J Melchers; Paul E Verweij
Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2003;9(7):750-3.
2003: Javier Afeltra; Paul E Verweij
Antifungal activity of nonantifungal drugs.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2003;22(7):397-407.
2003: Roxana G Vitale; Jacques Meis; Johan W Mouton; Paul E Verweij
Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media.
The Journal of antimicrobial chemotherapy 2003;52(1):65-70.
2003: Eric Nulens; Cathrien Eggink; Antonius J M M Rijs; Pieter Wesseling; Paul E Verweij
Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole.
Journal of clinical microbiology 2003;41(5):2261-4.
2003: Roxana G Vitale; Javier Afeltra; G Sybren De Hoog; Antonius J M M Rijs; Paul E Verweij
In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera.
The Journal of antimicrobial chemotherapy 2003;51(5):1297-300.
2003: Joseph Meletiadis; Willem J G Melchers; Jacques Meis; Patrick J J C van den Hurk; G Jannes; Paul E Verweij
Evaluation of a polymerase chain reaction reverse hybridization line probe assay for the detection and identification of medically important fungi in bronchoalveolar lavage fluids.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2003;41(1):65-74.
2003: Eric Dannaoui; Antonius J M M Rijs; Paul E Verweij
Invasive infections due to Apophysomyces elegans.
Mayo Clinic proceedings. Mayo Clinic 2003;78(2):252-3.
2003: Eric Nulens; Cathrien Eggink; Paul E Verweij
Combination therapy for keratitis by the fungus Scedosporium.
Cornea 2003;22(1):92.
2003: Joseph Meletiadis; Johan W Mouton; Jacques Meis; Paul E Verweij
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.
Antimicrobial agents and chemotherapy 2003;47(1):106-17.
2003: Eric Dannaoui; Joseph Meletiadis; Johan W Mouton; Jacques Meis; Paul E Verweij
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
The Journal of antimicrobial chemotherapy 2003;51(1):45-52.
2002: Javier Afeltra; Eric Dannaoui; Jacques Meis; Juan L Rodriguez-Tudela; Paul E Verweij
In vitro synergistic interaction between amphotericin B and pentamidine against Scedosporium prolificans.
Antimicrobial agents and chemotherapy 2002;46(10):3323-6.
2002: D T A Te Dorsthorst; Paul E Verweij; Joseph Meletiadis; M Bergervoet; Nieko Punt; Jacques Meis; Johan W Mouton
In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach.
Antimicrobial agents and chemotherapy 2002;46(9):2982-9.
2002: Joseph Meletiadis; Johan W Mouton; Jacques Meis; Bianca A Bouman; Paul E Verweij
Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species.
Journal of clinical microbiology 2002;40(8):2876-85.
2002: Eric Dannaoui; Javier Afeltra; Jacques Meis; Paul E Verweij
In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.
Antimicrobial agents and chemotherapy 2002;46(8):2708-11.
2002: Paul E Verweij; D T A Te Dorsthorst; Antonius J M M Rijs; Hilly G De Vries-Hospers; Jacques Meis
Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.
Journal of clinical microbiology 2002;40(7):2648-50.
2002: N M A Blijlevens; J Peter Donnelly; Jacques Meis; Paul E Verweij; Ben E de Pauw
Aspergillus galactomannan antigen levels in allogeneic haematopoietic stem cell transplant recipients given total parenteral nutrition.
Transplant infectious disease : an official journal of the Transplantation Society 2002;4(2):64-5.
2002: Javier Afeltra; Jacques Meis; Roxana G Vitale; Johan W Mouton; Paul E Verweij
In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.
Antimicrobial agents and chemotherapy 2002;46(6):2029-31.
2002: Roxana G Vitale; Johan W Mouton; Javier Afeltra; Jacques Meis; Paul E Verweij
Method for measuring postantifungal effect in Aspergillus species.
Antimicrobial agents and chemotherapy 2002;46(6):1960-5.
2002: Eric Dannaoui; Johan W Mouton; Jacques Meis; Paul E Verweij
Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.
Antimicrobial agents and chemotherapy 2002;46(6):1953-9.
2002: Eric Dannaoui; Jacques Meis; Johan W Mouton; Paul E Verweij
In vitro susceptibilities of Zygomycota to polyenes.
The Journal of antimicrobial chemotherapy 2002;49(5):741-4.
2002: D T A Te Dorsthorst; Paul E Verweij; Jacques Meis; Nieko Punt; Johan W Mouton
Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates.
Antimicrobial agents and chemotherapy 2002;46(3):702-7.
2002: Joseph Meletiadis; Jacques Meis; Johan W Mouton; Juan Luis Rodriquez-Tudela; J Peter Donnelly; Paul E Verweij
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.
Antimicrobial agents and chemotherapy 2002;46(1):62-8.
2001: Joseph Meletiadis; Johan W Mouton; Jacques Meis; Bianca A Bouman; P J Donnelly; Paul E Verweij
Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species.
Journal of clinical microbiology 2001;39(12):4256-63.
2001: Joseph Meletiadis; Johan W Mouton; Jacques Meis; Bianca A Bouman; J Peter Donnelly; Paul E Verweij
Colorimetric assay for antifungal susceptibility testing of Aspergillus species.
Journal of clinical microbiology 2001;39(9):3402-8.
2001: Javier Afeltra; Jacques Meis; Johan W Mouton; Paul E Verweij
Prevention of invasive aspergillosis in AIDS by sulfamethoxazole.
AIDS (London, England) 2001;15(8):1067-8.
2001: Joseph Meletiadis; Jacques Meis; Johan W Mouton; Paul E Verweij
Analysis of growth characteristics of filamentous fungi in different nutrient media.
Journal of clinical microbiology 2001;39(2):478-84.
2001: Rocus R Klont; Jacques Meis; Paul E Verweij
Critical assessment of issues in the diagnosis of invasive aspergillosis.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2001;7 Suppl 2():32-7.
2000: Paul E Verweij; Corry M R Weemaes; Jo H A J Curfs; Stephane Bretagne; Jacques Meis
Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis.
Journal of clinical microbiology 2000;38(10):3900-1.
2000: Joseph Meletiadis; Jacques Meis; G Sybren De Hoog; Paul E Verweij
In vitro susceptibilities of 11 clinical isolates of Exophiala species to six antifungal drugs.
Mycoses 2000;43(7-8):309-12.
2000: Joseph Meletiadis; Jacques Meis; Johan W Mouton; J Peter Donnelly; Paul E Verweij
Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method.
Journal of clinical microbiology 2000;38(8):2949-54.
2000: Jacques Meis; R A Schouten; Paul E Verweij; W Dolmans; J F Wetzels
Atypical presentation of Madurella mycetomatis mycetoma in a renal transplant patient.
Transplant infectious disease : an official journal of the Transplantation Society 2000;2(2):96-8.
2000: Paul E Verweij; Jacques Meis
Microbiological diagnosis of invasive fungal infections in transplant recipients.
Transplant infectious disease : an official journal of the Transplantation Society 2000;2(2):80-7.
2000: Joseph Meletiadis; Johan W Mouton; Juan L Rodriguez-Tudela; Jacques Meis; Paul E Verweij
In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans.
Antimicrobial agents and chemotherapy 2000;44(2):470-2.
2000: Paul E Verweij; J Figueroa; J Van Burik; M D Holdom; Eduardo Dei-Cas; B L Gómez; maria jose Mendes Giannini
Clinical applications of non-culture based methods for the diagnosis and management of opportunistic and endemic mycoses.
Medical mycology : official publication of the International Society for Human and Animal Mycology 2000;38 Suppl 1():161-71.
1999: M F VandenBergh; Paul E Verweij; Andreas Voss
Epidemiology of nosocomial fungal infections: invasive aspergillosis and the environment.
Diagnostic microbiology and infectious disease 1999;34(3):221-7.
1999: Paul E Verweij; M F van den Bergh; P M Rath; B E de Pauw; Andreas Voss; Jacques Meis
Invasive aspergillosis caused by Aspergillus ustus: case report and review.
Journal of clinical microbiology 1999;37(5):1606-9.
1999: Paul E Verweij; I M Breuker; Antonius J M M Rijs; Jacques Meis
Comparative study of seven commercial yeast identification systems.
Journal of clinical pathology 1999;52(4):271-3.
1999: Paul E Verweij; K Brinkman; H P Kremer; B J Kullberg; Jacques Meis
Aspergillus meningitis: diagnosis by non-culture-based microbiological methods and management.
Journal of clinical microbiology 1999;37(4):1186-9.
1998: Paul E Verweij; M Mensink; Antonius J M M Rijs; J Peter Donnelly; Jacques Meis; David W Denning
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
The Journal of antimicrobial chemotherapy 1998;42(3):389-92.
1998: Paul E Verweij; Z Erjavec; W Sluiters; W Goessens; M Rozenberg-Arska; Y J Debets-Ossenkopp; H F Guiot; Jacques Meis
Detection of antigen in sera of patients with invasive aspergillosis: intra- and interlaboratory reproducibility. The Dutch Interuniversity Working Party for Invasive Mycoses.
Journal of clinical microbiology 1998;36(6):1612-6.
1998: Paul E Verweij; KL Oakley; J Morrissey; Graham Morrissey; David W Denning
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Antimicrobial agents and chemotherapy 1998;42(4):873-8.
1998: Paul E Verweij; D Poulain; T Obayashi; Thomas Patterson; David W Denning; J Ponton
Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections.
Medical mycology : official publication of the International Society for Human and Animal Mycology 1998;36 Suppl 1():146-55.
1997: Johan L Severens; J Peter Donnelly; Jacques Meis; Pieter F De Vries Robbé; Ben E de Pauw; Paul E Verweij
Two strategies for managing invasive aspergillosis: a decision analysis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(5):1148-54.
1997: Paul E Verweij; M van Kasteren; J van de Nes; G Sybren De Hoog; B E de Pauw; Jacques Meis
Fatal pulmonary infection caused by the basidiomycete Hormographiella aspergillata.
Journal of clinical microbiology 1997;35(10):2675-8.
1997: Paul E Verweij; Andreas Voss; J Peter Donnelly; B E de Pauw; Jacques Meis
Wooden sticks as the source of a pseudoepidemic of infection with Rhizopus microsporus var. rhizopodiformis among immunocompromised patients.
Journal of clinical microbiology 1997;35(9):2422-3.
1997: C M A Swanink; Jacques Meis; Antonius J M M Rijs; J Peter Donnelly; Paul E Verweij
Specificity of a sandwich enzyme-linked immunosorbent assay for detecting Aspergillus galactomannan.
Journal of clinical microbiology 1997;35(1):257-60.
1996: Paul E Verweij; F Smedts; T Poot; P Bult; J A A Hoogkamp-Korstanje; Jacques Meis
Immunoperoxidase staining for identification of Aspergillus species in routinely processed tissue sections.
Journal of clinical pathology 1996;49(10):798-801.
1996: Paul E Verweij; Jacques Meis; Jacqueline Sarfati; J A A Hoogkamp-Korstanje; Jean-Paul Latgé; Willem J G Melchers
Genotypic characterization of sequential Aspergillus fumigatus isolates from patients with cystic fibrosis.
Journal of clinical microbiology 1996;34(10):2595-7.
1995: Paul E Verweij; Jean-Paul Latgé; Antonius J M M Rijs; Willem J G Melchers; B E De Pauw; J A A Hoogkamp-Korstanje; Jacques Meis
Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for hematological malignancies.
Journal of clinical microbiology 1995;33(12):3150-3.
1995: Paul E Verweij; D Stynen; Antonius J M M Rijs; B E de Pauw; J A A Hoogkamp-Korstanje; Jacques Meis
Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients.
Journal of clinical microbiology 1995;33(7):1912-4.
1995: Paul E Verweij; Jacques Meis; P van den Hurk; J Zoll; R A Samson; Willem J G Melchers
Phylogenetic relationships of five species of Aspergillus and related taxa as deduced by comparison of sequences of small subunit ribosomal RNA.
Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology 1995;33(3):185-90.
1995: Paul E Verweij; Antonius J M M Rijs; B E De Pauw; Alphons Horrevorts; J A A Hoogkamp-Korstanje; Jacques Meis
Clinical evaluation and reproducibility of the Pastorex Aspergillus antigen latex agglutination test for diagnosing invasive aspergillosis.
Journal of clinical pathology 1995;48(5):474-6.
1994: Willem J G Melchers; Paul E Verweij; P van den Hurk; Alex Van Belkum; B E De Pauw; J A A Hoogkamp-Korstanje; Jacques Meis
General primer-mediated PCR for detection of Aspergillus species.
Journal of clinical microbiology 1994;32(7):1710-7.